| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 05/25/2000 | WO2000028954A1 Method for inhibiting dental resorptive lesions |
| 05/25/2000 | WO2000028835A1 A method for supplying bioavailable methionine to a cow |
| 05/25/2000 | WO2000012111A3 Selective treatment of endothelial somatostatin receptors |
| 05/25/2000 | WO2000009543A3 Hepatitis c inhibitor tri-peptides |
| 05/25/2000 | DE19853487A1 Use of dialkyl fumarate for treating transplant rejection and autoimmune disease |
| 05/25/2000 | DE19853278A1 New 4-amino-2-aryl-cyclopentapyrimidine derivatives are activators of soluble guanylate cyclase, useful for treating or preventing e.g. thrombosis and restenosis |
| 05/25/2000 | CA2351644A1 Pyrimidine derivatives and processes for the preparation thereof |
| 05/25/2000 | CA2351576A1 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
| 05/25/2000 | CA2350914A1 Treatment of tumors by administration of growth hormone releasing compounds and their antagonists |
| 05/25/2000 | CA2350785A1 31 human secreted proteins |
| 05/25/2000 | CA2350532A1 Excitatory amino acid receptor modulators |
| 05/25/2000 | CA2350443A1 Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors |
| 05/25/2000 | CA2350415A1 Inflammation-associated genes |
| 05/25/2000 | CA2350391A1 Method for inhibiting macrophage infiltration using monoclonal anti-alpha-d-antibodies |
| 05/25/2000 | CA2349837A1 Lysozyme fusion proteins in infections |
| 05/25/2000 | CA2349762A1 Human tslp dna and polypeptides |
| 05/25/2000 | CA2349575A1 Nitrosated and nitrosylated h2 receptor antagonist compounds, compositions and methods of use |
| 05/25/2000 | CA2348676A1 Method for preparing (2s)-1-¬ (2r,3s)-5- chloro-3-(2- chlorophenyl) -1-(3,4-dimethoxy benzenesulphonyl) -3-hydroxy-2, 3-dihydro-1h- indole-2-carbonyl| pyrrolidine-2- carboxamide |
| 05/25/2000 | CA2348459A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 05/24/2000 | EP1002862A1 Methods of diagnosing or treating neurological diseases |
| 05/24/2000 | EP1002797A1 4,5-DIHYDRO- 1H]-BENZ g]INDAZOLE-3-CARBOXYLIC ACID DERIVATIVES |
| 05/24/2000 | EP1002540A1 Composition comprising panax pseudo ginseng and eucommiae ulmoides |
| 05/24/2000 | EP1002092A1 Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof |
| 05/24/2000 | EP1002069A1 Peptides containing the motif igd and their use as cell migration modulators |
| 05/24/2000 | EP1001990A1 Protein that binds trail |
| 05/24/2000 | EP1001976A2 Peptides having potassium channel opener activity |
| 05/24/2000 | EP1001974A1 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001973A1 Compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 05/24/2000 | EP1001955A1 1,2,4-triazolo 4,3-b]pyrido 3,2-d]pyridazine derivatives and pharmaceutical compositions containing them |
| 05/24/2000 | EP1001933A1 Caspases and apoptosis |
| 05/24/2000 | EP1001930A2 N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases |
| 05/24/2000 | EP1001801A1 Product comprising at least a double stranded rna combined with at least an antiviral agent |
| 05/24/2000 | EP1001796A1 Antacid and papain combination |
| 05/24/2000 | EP1001787A1 Liver protection or treatment agents comprising asiatic acid derivatives as the active component |
| 05/24/2000 | EP1001768A1 Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor |
| 05/24/2000 | EP1001764A1 Heterocyclic amide compounds as cell adhesion inhibitors |
| 05/24/2000 | EP1001737A1 Intra-oral antioxidant preparations |
| 05/24/2000 | EP0794788A4 Hepatic-directed compounds and reagents for preparation thereof |
| 05/24/2000 | EP0626969B1 CoA-IT AND PAF INHIBITORS |
| 05/24/2000 | CN1254375A Motilin homologs |
| 05/24/2000 | CN1254337A N-hydroxy 4-sulfonyl butyramide compounds |
| 05/24/2000 | CN1254335A Nicotinamide derivatives |
| 05/24/2000 | CN1254290A Genes coding proteins for early liver development and their use in diagnosing and treating liver disease |
| 05/24/2000 | CN1254286A Composition for prevention of hepatic steatosis |
| 05/24/2000 | CN1254285A Use of zinc hyaluronate against peptic ulcer |
| 05/24/2000 | CN1253948A Substituted tricyclic compound |
| 05/24/2000 | CN1253832A Metabolism-supporting preparation for curing hepatic failure and its preparation method |
| 05/24/2000 | CN1253831A Baoyuan kidney-strengthening bag |
| 05/24/2000 | CN1253830A Chinese medicine prescription for curing hepatitis, cholangitis, pancreatitis and cirrhosis |
| 05/24/2000 | CN1253823A Chinese patent medicine for curing hepatitis B |
| 05/24/2000 | CN1253816A Capsule for curing chronic enteritis |
| 05/24/2000 | CN1253807A Tea with functions of dispelling effect of alcohol, nourishing stomach and protecting liver |
| 05/24/2000 | CN1052725C Tricyclic vasopressin antagonists |
| 05/24/2000 | CN1052723C Bicyclic aromatic compounds as therapeutic agents, its preparing method and drug composition containing said compound |
| 05/24/2000 | CN1052650C Process for preparing Qingkailing powder injection |
| 05/24/2000 | CN1052646C Capsule for curing gastropathy and its preparing method |
| 05/24/2000 | CN1052645C Traditional Chinese medicine 'Zhenhuang' powder and its producing method |
| 05/24/2000 | CN1052642C Instant powder made from fresh dendrobe |
| 05/23/2000 | US6066717 RsbW-1 protein |
| 05/23/2000 | US6066678 Alkylated and crosslinked polymer comprises the reaction product of polymers of given formula having amine containing repeat units with at least one aliphatic alkylating agent and a crosslinking agent; administering to remove bile salts |
| 05/23/2000 | US6066657 For the treatment of disease states associated with proteins which mediate cellular activity, for example by inhibiting tumor necrosis factor or phosphodiesterase iv |
| 05/23/2000 | US6066654 Methods for treating disorders associated with the central nervous system using optically pure (-) cisapride |
| 05/23/2000 | CA2200959C 2,7-substituted octahydro-1h-pyrido[1,2-a]pyrazine derivatives |
| 05/23/2000 | CA2171637C Substituted azaheterocyclecarboxylic acids |
| 05/18/2000 | WO2000028039A2 Identification of senv genotypes |
| 05/18/2000 | WO2000028033A2 Nucleic acids and polypeptides having altered expression in the t84 gut barrier model |
| 05/18/2000 | WO2000028019A2 Antisense oligomer |
| 05/18/2000 | WO2000027868A2 Connective tissue growth factor (ctgf) and methods of use |
| 05/18/2000 | WO2000027850A2 Crf receptor antagonists and methods relating thereto |
| 05/18/2000 | WO2000027842A1 Compounds |
| 05/18/2000 | WO2000027823A1 Gastrin and cholecystokinin receptor ligands |
| 05/18/2000 | WO2000027822A2 Tricyclic pyrazole derivatives |
| 05/18/2000 | WO2000027819A2 Antrhranilic acid amides and the use thereof as medicaments |
| 05/18/2000 | WO2000027815A2 N-substituted azacycles, their preparation and their use as orl-1 receptor ligands |
| 05/18/2000 | WO2000027808A1 N-arylsulfonyl amino acid omega amides |
| 05/18/2000 | WO2000027805A1 Substituted 3,3-diamino-2-propenenitriles, their preparation and use |
| 05/18/2000 | WO2000027414A2 Inhibition of the formation of vascular hyperpermeability |
| 05/18/2000 | WO2000027410A2 Composition and method for increasing weight gain and feed efficiency |
| 05/18/2000 | WO2000027409A1 Production of a biological factor and creation of an immunologically privileged environment using genetically altered sertoli cells |
| 05/18/2000 | WO2000027392A1 Chromone enteric release formulation |
| 05/18/2000 | WO2000027378A2 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases |
| 05/18/2000 | WO2000027377A2 Phosphinate peptide analogs for the treatment of fibrotic disorders |
| 05/18/2000 | WO2000027366A1 Pharmaceutical formulation comprising omeprazole |
| 05/18/2000 | WO2000027359A1 An inhalation system |
| 05/18/2000 | WO1999024470A8 Mammalian milk growth factor |
| 05/18/2000 | DE19848260A1 Fumarsäure-Mikrotabletten Fumaric microtablets |
| 05/18/2000 | CA2351167A1 Nucleic acids and polypeptides having altered expression in the t84 gut barrier model |
| 05/18/2000 | CA2351063A1 A system for administering a bioactive agent by inhalation comprising a lipid mixture comprising phosphatidylcholine |
| 05/18/2000 | CA2350235A1 Tricyclic pyrazole derivatives |
| 05/18/2000 | CA2350208A1 Antrhranilic acid amides and the use thereof as medicaments |
| 05/18/2000 | CA2350182A1 Connective tissue growth factor (ctgf) and methods of use |
| 05/18/2000 | CA2349904A1 Crf receptor antagonists and methods relating thereto |
| 05/18/2000 | CA2349445A1 Antisense oligomer |
| 05/18/2000 | CA2348946A1 Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases |
| 05/18/2000 | CA2348934A1 Phosphinate peptide analogs for the treatment of fibrotic disorders |
| 05/18/2000 | CA2348727A1 Composition and method for increasing weight gain and feed efficiency |
| 05/18/2000 | CA2347916A1 Inhibition of the formation of vascular hyperpermeability |
| 05/18/2000 | CA2346108A1 Gastrin and cholecystokinin receptor ligands |
| 05/17/2000 | EP1000930A2 Tachykinin antagonists |
| 05/17/2000 | EP1000927A2 Excitatory amino acid receptor modulators |